$CVI

CVR Energy (NYSE:CVI) Stock Price Expected to Rise, Mizuho Analyst Says

Mizuho raised its CVR Energy (NYSE:CVI) price target to $35 from $32 and kept an “underperform” rating, implying about 10.27% upside from the prior close, according to Benzinga. Other firms issued mixed ratings. CVI shares opened at $31.74. In its Apr. 29 quarter, CVR reported EPS of -$1.24 and revenue of $1.98B.

Original reporting
Published May 27, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CVR Energy (NYSE:CVI) Stock Price Expected to Rise, Mizuho Analyst Says — source image
Decision brief

The 30-second read

$CVIBullishMed
01

Why it matters

The primary tradable input is the Mizuho target increase, but the broader sell/underperform backdrop and the recent earnings miss raise the risk of a muted rally.

02

Market read

Analyst target lift may support a short-term technical/positioning bounce, but consensus remains heavily negative and fundamentals recently disappointed.

03

What to watch

The article highlights negative net margin and negative ROE from the last quarter; without margin improvement, price-target upside may not translate into earnings revisions.

Relevance 8/10Timing: Immediate (analyst note published Wednesday) with potential follow-through over subsequent sessions as traders reprice targets.

Background

The piece summarizes analyst rating/target changes for CVR Energy and reiterates its latest quarterly results (EPS miss, revenue beat) plus current technical/valuation snapshot.

Company-level read

Ticker impact

$CVIBullishMedium confidence
Context

Mizuho lifted its CVR Energy price objective from $32 to $35 and kept an “underperform” stance, implying ~10% upside versus the prior close.

Expected impact

Near-term bounce possible toward the new target, but upside may be capped unless fundamentals re-accelerate after the April earnings miss.

Evidence & confidence

The article is driven by analyst target changes rather than new company fundamentals; however, it references a recent EPS miss and ongoing sell/underperform consensus, which can limit follow-through.

Market effects

Reinforces that downstream refiners can see target dispersion even after earnings misses, keeping attention on refining margins and earnings quality.

Limited; CVR is US-focused and the catalyst is analyst-driven rather than a regional macro shock.

Low; no direct global event is cited beyond general oil-and-gas equity sentiment.

Counterpoint

Despite the raised target, multiple firms still rate CVI Sell/underperform, suggesting the market may discount the target increase as insufficient to change the risk profile.

Key entities

  • CVR Energy

    Independent downstream energy company; subject of the analyst price-target lift and the recent earnings results referenced in the article.

  • Mizuho

    Raised CVI price objective from $32 to $35 while maintaining an underperform rating.

Related articles

$CVIMed

Moody’s Upgrades CVR Energy Credit Rating to B1

Moody’s upgraded CVR Energy Inc. (CVI) to B1 from B2, citing improved financials, lower debt, and strong cash flow. The agency also raised its senior unsecured debt rating to B2 and liquidity assessment to SGL-1, maintaining a stable outlook. CVR operates two U.S. refineries and holds a stake in CVR Partners LP (UAN). Moody’s noted risks like operational scale and regulatory uncertainty but highlighted strong liquidity, including $600M in cash and a $550M credit facility.

$CVIMed

CVR Energy Reports Second Quarter 2026 Results

CVR ENERGY INC (CVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CVR Energy Reports Second Quarter 2026 Results • Second quarter 2026 net loss attributable to CVR Energy stockholders of $3 million; Adjusted EBITDA of $209 million • Declared cash dividend of 10 cents for the second quarter 2026 • CVR Partners, LP (“CVR Partners”) a

$JNJMed

Johnson & Johnson Reports Early JNJ-6143 Responses in Prostate Cancer Trial

Johnson & Johnson reported positive results for its investigational drug JNJ-6143 in a Phase 1 prostate cancer trial, with 77% of patients showing a confirmed PSA decline. The company selected a 50-mg daily dose for Phase 2 testing. The drug is designed to target the androgen receptor and BRD4 protein. Johnson & Johnson acquired Halda Therapeutics, the drug's original developer, for $3.05 billion in 2025.